Pharmaxis Limited (ASX:PXS) has filed a minor resubmission with the Pharmaceutical Benefits Advisory Committee (PBAC) for its new drug, Bronchitol.
The product’s been developed to help clear mucus, improve lung function, and reduce exacerbations in patients with cystic fibrosis.
The submission will be considered by the committee at a meeting in March.
Pharmaxis chief executive Alan Robertson says the resubmission follows a constructive discussion with the Committee’s recently appointed chair, and Pharmaxis remains committed to securing satisfactory reimbursement for the drug.
Shares surged 54 per cent on October 24, after European regulators not only reversed a negative ruling on Bronchitol, but recommended its use.
Pharmaxis reported a net loss of $45.7 million for the six months to June.
